Background--Levels of LDL (low-density lipoprotein) cholesterol in the population are declining, and increasing attention is being focused on residual lipid-related pathways of atherosclerotic cardiovascular disease risk beyond LDL cholesterol. Among individuals with low (<130 mg/dL) LDL cholesterol, we undertook detailed profiling of circulating atherogenic lipoproteins in relation to incident cardiovascular disease in 2 populations.
P opulation levels of LDL-c (low-density lipoprotein cholesterol) are declining with increasing adherence to healthy lifestyle and pharmacologic interventions.
1,2 However, cardiovascular disease (CVD) events remain prevalent among individuals with low or normal LDL-c, both pretreatment and during high-intensity statin therapy, 3 a phenomenon referred to as residual risk. In parallel, as population levels of LDL-c have declined over recent years, studies have demonstrated time-dependent changes in the composition and morphology of human atherosclerotic plaque, 4 suggesting shifting mechanisms of atherogenesis and plaque disruption amid this changing risk factor exposure and changing epidemiology of CVD. 5 Numerous studies have suggested that LDL-c does not account for all of the risk conferred by atherogenic plasma lipids and the insulating lipid and protein assemblies that transport them in the bloodstream, lipoproteins, 6, 7 and thus, it is possible that residual lipid and lipoprotein risk pathways or markers that were previously eclipsed in significance by LDL-c are likely to emerge as increasingly important determinants of CVD.
To understand the residual markers of lipid-and lipoprotein-related risk in the era of LDL-c reduction and to forecast the emergence of such alternate risk pathways, we examined populations of individuals with low (<130 mg/dL) LDL-c with advanced lipoprotein profiling. Detailed lipoprotein phenotyping by proton nuclear magnetic resonance ( 1 H NMR) spectroscopy can quantify concentrations, subclass distributions, composition, and size of atherogenic LDL particles (LDL-p) and very low-density lipoprotein particles (VLDL-p) in circulation. 8, 9 Accordingly, this study was designed ( Figure 1 ) to (1) identify potential NMR-measured lipoproteins associated with incident CVD risk in a population of individuals with naturally normal or low LDL-c, (2) understand the changes in the lipoprotein milieu accompanying high-intensity statin therapy, and (3) identify lipoprotein subclasses associated with onstatin risk of CVD events despite achieved low levels of LDL-c. We sought to extend the findings by examining an independent, diverse cohort of individuals referred for cardiac catheterization (CATHGEN).
Material and Methods

Study Design and Population
The primary study population is derived from a primaryprevention randomized controlled clinical trial of rosuvastatin 20 mg versus placebo (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin, JUPITER; NCT00239681). 10 The JUPITER trial randomized individuals (women ≥60 years, men ≥50 years) without prior history of CVD or diabetes mellitus, all of whom had LDL-c <130 mg/dL, high-sensitivity C-reactive protein (hsCRP ≥2.0 mg/L), and triglycerides ≤500 mg/dL. The relative risk reduction for the primary incident CVD end point was 44%. 10 We performed 1 H NMR lipoprotein measurements on fasting blood samples from 11 984 participants (of whom 9222 also had 1-year samples) who consented to and provided additional blood collection with sufficient plasma available. In the placeboallocated arm, baseline lipoprotein measurements were used to identify lipoproteins associated with risk of incident CVD in untreated individuals. In the statin-allocated arm, (1) change in lipoprotein measurements from baseline to 12 months after randomization was used to understand the effects of statin therapy on lipoprotein subfractions, and (2) on-statin (12 month) lipoprotein measurements were used to identify lipoproteins associated with residual on-statin risk of incident CVD.
Laboratory Analysis
Standard lipid measurements were performed on fasting samples by a central laboratory. 11 LDL-c was calculated by the Friedewald equation (total cholesterol minus HDL-c minus triglycerides/5) when triglycerides were <400 mg/dL, and measured by ultracentrifugation when triglycerides were ≥400 mg/dL. Triglycerides were measured using a colorimetric assay. Measurement of apolipoproteins B (apoB) was via immunonephelometry by using a Behring nephelometric assay. • Among a population intended to represent the growing number of individuals with low low-density lipoprotein cholesterol, atherogenic lipoprotein particle concentrations (low-density lipoprotein and very low-density lipoprotein particles) were markers of residual atherosclerotic cardiovascular disease risk.
• Among individuals with the lowest low-density lipoprotein cholesterol on statin, the smallest subclass of very lowdensity lipoprotein was strongly associated with residual risk.
• This risk was related to the cholesterol carried in small very low-density lipoprotein, and not triglyceride.
• Similar patterns were observed in an independent, diverse population of individuals referred for cardiac catheterization at a single center.
What Are the Clinical Implications?
• 
Outcomes
The primary outcome was the trial primary end point, a composite incident CVD end point defined as the occurrence of either myocardial infarction, stroke, hospitalization for unstable angina, arterial revascularization, or cardiovascular death. 10 An expanded end point of CVD or all-cause mortality was also examined, consistent with prior JUPITER biomarker analyses. 14 
Extension to Other Populations
We sought to extend the JUPITER findings in an independent, prospective cohort encompassing a diverse population referred for cardiac catheterization at Duke University from 2001 to 2010 (CATHGEN; dmpi.duke.edu/cathgen). 15 As in JUPITER, we focused on individuals with LDL-c <130 mg/dL and TG <500 mg/dL (N=2149 individuals). (The hsCRP was not routinely measured.) We also examined the subset of participants with confirmed statin prescription (N=833) as well as, more broadly, risks among all comers in the cohort without LDL-c stratification. Lipoprotein subclasses were measured using the same NMR assay as in JUPITER. Fatal or nonfatal myocardial infarction was the primary outcome in this mixed population of individuals both with and without established CVD. Cox models included all covariables used in the JUPITER analyses except for hsCRP, which was not routinely measured.
Statistical Analyses
Medians (25th, 75th percentiles) were displayed for continuous variables. Lipoprotein change was evaluated using the Wilcoxon signed-rank test. Exposure time was calculated as the time from randomization to end-point occurrence or censoring (the latter including censoring at time of noncardiovascular mortality). Cox proportional hazards models were used to calculate hazard ratios and 95% CIs for CVD in relation to per-SD increments in measures. Nonnormally distributed data were (natural) log transformed. Additionally, risk was examined across lipoprotein tertiles. Models were adjusted for age, sex, race, smoking, family history of premature coronary disease, body-mass index, systolic blood pressure, fasting glucose, and hsCRP. Sensitivity analyses mutually adjusting for other NMR lipoprotein subclasses were performed, 16 as well as adjusting for HDL-c. Additionally, a minority of individuals in these analyses had events before ontreatment NMR measurement; however, the majority of events occurred after measurement, and in sensitivity analyses beginning the follow-up at time of NMR measurement, the results were not appreciably different, although with less power some associations were no longer significant. We assessed predictive model performance by assessing the change in Harrell C-index (and quantitatively with the likelihood ratio test) for 2 hierarchically nested models predicting primary CVD events: (1) Figure 2 . Schematic representation of the median proportion of atherogenic (LDL and VLDL) lipoprotein subclasses (median subclass particle concentration divided by median total LDL+VLDL particle concentration measured with NMR) at baseline in fasting samples in the rosuvastatin arm pre-treatment. IDL-p indicates intermediate density lipoprotein particle concentration; LDL-p, low density lipoprotein particle concentration; NMR, nuclear magnetic resonance; VLDL-p, very low density lipoprotein particle concentration. 
Results
Baseline Characteristics
Study participants had a median (25th, 75th percentiles) age of 66 (60, 71) years, and were 36% female. Except for race/ ethnicity, participants in the current study were generally representative of those in the original JUPITER trial (Table 1) . 10 Median baseline LDL-c was 109 (95, 120) mg/ dL, triglycerides were 119 (87, 169) mg/dL, and hsCRP was 4.10 (2.75, 6.70) mg/L. Total LDL-p and apoB were strongly correlated at baseline (Table 2) , and LDL-p was the most abundant atherogenic lipoprotein ( Figure 2 ; Table 3 ). NMR-measured VLDL/CM triglyceride was strongly correlated with chemically measured triglycerides and with large VLDL-p (and progressively less with medium and small VLDL-p). Calculated remnant cholesterol was (as expected based on the use of the Friedewald equation) perfectly correlated with triglyceride (r=1.00), moderately with apoB, non-HDL-c, and VLDL-c (r=0.48, 0.60, and 0.58, respectively), and not with LDL-c (r=0.01).
Baseline Risk of Incident CVD
Among the 11 984 JUPITER participants, a total of 296 primary events and 489 expanded end points occurred over a median follow-up of 2.0 (maximum 5.0) years, representing 27 864 person-years. Among participants in the placebo-allocated arm (N=6050; 189 events; Figure 3 ), LDL-c was not associated with increased risk of the primary end point, but significant associations were observed for non-HDL-c ( Table 4 ), associations were generally attenuated and became nonsignificant for non-HDL-c and apoB. Tertile analysis demonstrated a graded increase in risk with increasing levels of these markers but not LDL-c (Table 5) .
For NMR-measured lipoproteins, a significant association was noted for LDL-p and the primary end point (1.19 [1.02, 1.38]) but not for the individual LDL subclasses. Smaller LDL size was a marker of increased risk, but this was no longer significant after additionally adjusting for LDL-p-as previously suggested 16 -and HDL-c.
Conversely, most VLDL-p subfractions, as well as total VLDL-p and NMR-determined VLDL/CM triglycerides, were associated with increased risk of the primary (Figure 3) or expanded (Table 4 ) end point. The magnitude of this risk was similar to that of chemically measured triglycerides. Because VLDL-p subfractions were comparably associated with increased risk, there was no independent association for average VLDL particle size. Total NMR-measured VLDL-c was not significantly associated with the primary or expanded end points at baseline. Overall, when the baseline analysis was performed in the entire cohort adjusting for 
Residual Risk of CVD
Among participants in the statin-allocated arm with on-statin measures (N=4386), median LDL-c was 55 mg/dL, and triglyceride was 102 mg/dL. In this population, standard lipid and apolipoprotein measures were marginally associated with risk (73 primary end-point events and 108 expanded endpoint events; Figure 5 ; Tables 4 and 6 ), including apoB, non-HDL-c, and LDL-c. On statin therapy, each SD increment in total VLDL-p, driven by the smallest VLDL-p subclass, was associated with residual risk ( Figure 5 ). Adjusted hazard ratios (95%CIs) per increasing tertile of on-treatment small VLDL-p were 1.00 (Ref. an Intervention Trial; LDL-c, low-density lipoprotein cholesterol; LDL-p, low-density lipoprotein particle concentration; non-HDL-c, non-high-density lipoprotein cholesterol concentration; RC, calculated remnant cholesterol; TG, triglycerides; VLDL-c, very low-density lipoprotein cholesterol; VLDL-p, very low-density lipoprotein particle concentration. *Adjusted for age, sex, race, smoking status, family history of premature coronary disease, body-mass index, systolic blood pressure, fasting glucose, and hsCRP. † LDL size was no longer associated with either end point after adjusting for LDL-p and HDL-c. The following biomarkers were natural-log-transformed: triglyceride, RC, small LDL-p, IDL-p, all VLDL-p subclasses, VLDL/CM triglycerides, and VLDL-c.
Secondary Cohort Examination
Participants in CATHGEN with LDL-c <130 mg/dL and triglycerides <500 mg/dL were demographically similar to JUPITER participants in age (mean [SD] 60.7AE11.7 years), sex (62.3% male), and racial (74.2% white) distribution as well as based on body-mass index (30.1AE7.4 kg/m 2 ) and systolic blood pressure (144AE25 mm Hg). Among these 2149 individuals, 154 events occurred over median (maximum) 5.0 (13.3) years of follow-up. Total VLDL-p was significantly associated with risk of myocardial infarction, driven by the small VLDL lipoprotein subclass ( Table 7) . As with larger VLDL-p subclasses, VLDL/CM triglyceride concentration was not significantly associated with risk. Although restriction to those confirmed as having a prescribed statin reduced sample size to only 833 individuals, the pattern of the associations was unchanged, but the confidence intervals in this much smaller subgroup were wider and no longer significant. When no LDL-c or statin-based selection criteria were applied, risk of myocardial infarction among all comers with NMR measurements in the cohort was not significantly associated with VLDL-p levels. Similarly, the magnitude of risk associated with LDL-p became larger as the cohort was progressively more selected based on LDL-c <130 mg/dL and statin prescription status.
Prediction Model Performance
In JUPITER the C-statistic (a measure of model discrimination) for the baseline CVD risk model (built with 12 clinical and standard lipid measure variables; 12 degrees of freedom) for the placebo group was not significantly changed (P=0.50) with 
Discussion
This study was designed to identify circulating lipoproteins measured by 1 H NMR associated with CVD risk among individuals with naturally or pharmacologically low (<130 mg/ dL) LDL-c. We observed that, among such individuals, risk was associated with lipoprotein particle concentration, including LDL and VLDL subfractions. Intriguingly, among individuals on statin therapy (median LDL-c 55 mg/dL), the lipoprotein subclass small VLDL-p (and its associated cholesterol) conferred an %70% per-SD increase in residual risk, corresponding to a 3.7-fold increase in risk among those in the highest tertile. These observations were extended using a distinct, diverse cohort referred for cardiac catheterization Tertiles derived from the baseline population. HR indicates hazard ratio; hsCRP, high-sensitivity C-reactive protein; IDL-p, intermediate-density particle concentration; LDL-c, low-density lipoprotein cholesterol; LDL-p, low-density lipoprotein particle concentration; non-HDL-c, non-high-density lipoprotein cholesterol concentration; RC, remnant cholesterol; Ref, reference value; VLDL-c, very low-density lipoprotein cholesterol; VLDL-p, very low-density lipoprotein particle concentration. *Adjusted for adjusted for age, sex, race, smoking status, family history of premature coronary disease, body-mass index, systolic blood pressure, fasting glucose, and hsCRP.
(CATHGEN); as refinement of the population based on LDL-c <130 mg/dL or statin prescription was undertaken, the magnitude of risk related to lipoprotein subclasses appeared amplified (including small VLDL-p). Exploratory analyses suggested that on-statin residual risk prediction could be significantly improved beyond known clinical and standard lipid risk factors with the inclusion of NMR-based VLDL measurements. Overall, our results suggest a potential role for VLDL lipoproteins in the development of CVD events, particularly among individuals with lower LDL-c-a rapidly growing population in clinical practice 1,2 in whom event rates nonetheless remain unacceptably high. 3, 17 We observed that baseline apoB and LDL-p were associated with risk of incident CVD. Although both measures were highly correlated (r=0.79), the magnitude of risk associated with apoB was somewhat greater than that for LDL-p, consistent with findings from the Women's Health Study.
14 In addition to LDL, apoB is also present on VLDL and lipoprotein(a), the latter of which also carried increased risk in JUPITER. 18 Triglycerides and VLDL/CM measures were associated with risk in the JUPITER placebo group, whereas the small VLDL-p subclass (but not triglycerides) was strongly associated with risk in the statin group. VLDL (also referred to as triglyceride-rich lipoproteins) are believed to confer atherogenic risk related to their cholesterol content (ie, remnant cholesterol), 19 which can be deposited directly into the arterial wall without modification. 20 Why the magnitude of risk related to VLDL-p appeared to differ based on statin allocation is unclear and deserves further investigation. It is possible that statin-related suppression of inflammation could modify the relationship between VLDL and atherosclerosis. 19 Our study is novel in its consideration of NMR-based atherogenic lipoprotein measures among dedicated populations of individuals with low (<130 mg/dL) LDL-c, an increasingly prevalent population in the era of LDL-c reduction. Our findings support and extend previous observations from other cohorts, wherein lipoprotein particle concentration measured by apoB and NMR (LDL-p) was associated with CVD events among statin-treated secondary prevention individuals. 21 Additionally, no other study has assessed the significance of on-statin levels of NMR-measured VLDL lipoproteins in relation to residual CVD risk. Our results help frame those of previous studies, wherein on-statin triglyceride levels have been inconsistently associated with residual risk, 22 suggesting the need for more detailed VLDL phenotyping. Our results also support and extend recent efforts to more comprehensively profile statin effects on the spectrum of the lipid and lipoprotein milieu. 23 The risk estimates observed with NMR are largely in agreement with those recently obtained in the same cohort using electrospray ion mobility, 24 except that stronger association was noted for NMR-measured small VLDL-p with residual risk. In JUPITER, measurements of small VLDL by NMR and ion mobility were only modestly correlated (Spearman r=0.22). In other cohorts, NMR and ion mobility have also demonstrated differential resolution of the proatherogenic effects of VLDL. 25 The basis for such differences may be due to methodological differences, with NMR providing better measurement of lipid-rich lipoprotein particles such as VLDL, while ion mobility may better capture protein-rich particles. Our study has several potential limitations. First, the follow-up duration in JUPITER was relatively short for a primary prevention study (due to early termination of the trial for benefit by the Data Safety and Monitoring Board). Nonetheless, event rates were sufficiently high to detect a number of expected and novel associations, and the longer follow-up in CATHGEN (median [maximum] 5.0 [13.3] years) suggested longitudinal extrapolation of these results. Second, all JUPITER study participants had elevated hsCRP. Systemic inflammation has been shown to affect the composition of the lipoprotein milieu, including VLDL. 26 At a minimum, it has been estimated that more than 1 in 50 adult Americans would meet the JUPITER inclusion criteria. 27 Furthermore, hsCRP was not part of the selection criteria in CATHGEN, suggesting that these findings may be more broadly generalizable. Finally, multiple comparisons were performed, increasing the chance of a type I error. However, examination of an independent cohort supported the key associations observed, and the findings are supported by prior biologic and epidemiological studies. Nonetheless, given the multiplicity of hypotheses tested, these results should be viewed as hypothesis-generating and require further validation in additional cohorts. In conclusion, among individuals with low (<130 mg/dL) LDLc, risk remains associated with lipoprotein particle concentration, including VLDL lipoproteins. We observed on-statin risk strongly associated with small VLDL-p-risk that appears to be triglyceride-independent and instead related to the cholesterol carried by these small VLDL particles. Overall, these hypothesis-generating findings draw attention to the potential importance of VLDL lipoproteins, in particular small remnant particles, which are associated with risk but are currently not the target of prediction or therapeutic intervention. Additional studies are needed to validate these findings and assess the potential causal role of these lipoproteins as determinants of CVD risk.
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